Stay updated with breaking news from Biomarin voxzogo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin. ....
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Friday said that the U.S. Food and Drug Administration has granted accelerated approval to Voxzogo, the first drug approved by the FDA ....
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Biomarin Pharmaceutical Inc. (BMRN):-Earnings: -$36.49 million in Q3 vs. $784.80 million in the same period last year. -EPS: -$0.20 ....
WASHINGTON (dpa-AFX) - California-based healthcare company, BioMarin Pharmaceutical Inc. (BMRN), provided an improved full-year outlook on Wednesday. The company has narrowed its net loss outlook ....
BioMarin: Phase 1/2 Study On Hemophilia A Shows Hemostatic Control With Valoctocogene Roxaparvovec WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), in an update on phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, said Wednesday that the safety profile of valoctocogene roxaparvovec in the study remains consistent with previously reported data with no delayed-onset treatment related adverse events. The company noted that the latest data update in the ongoing study represents the longest duration of clinical experience for any gene therapy in hemophilia A and demonstrates hemostatic control with valoctocogene roxaparvovec out to five years in the majority of patients in this study. ....